Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2021—Streck has launched its Zulu RT, a rapid, modular qPCR instrument. The instrument consists of four independent thermal modules. A user can operate any combination of modules—one module for a small sample set, leaving other modules for other users, or up to four modules simultaneously for a large sample set. It can perform a 40-cycle, six-channel real-time PCR in less than 20 minutes.
January 2021—The FDA authorized the first diagnostic test for at-home collection of patient samples to detect COVID-19 and influenza A and B. Quest Diagnostics’ RC COVID-19 +Flu RT-PCR Test for prescription use was authorized with Quest’s Self-Collection Kit for COVID-19 +Flu for individuals who are suspected of respiratory viral infection consistent with COVID-19 when home collection is determined to be appropriate by an individual’s health care provider.
January 2021—GenMark Diagnostics received FDA emergency use authorization for its ePlex Respiratory Pathogen Panel 2. The test provides results in less than two hours for more than 20 viruses and bacteria that cause respiratory infections, including COVID-19, flu, bronchitis, and the common cold.
January 2021—Nova Biomedical announced the availability of Nova Primary, a rapid blood glucose laboratory analyzer. Nova Primary fills the need for a glucose reference analyzer to replace the YSI Stat Plus 2300 Glucose and L-Lactate analyzer, which, as of July 2021, will no longer be supported by YSI, Inc.
January 2021—Qiagen has acquired the remaining 80.1 percent of NeuMoDx Molecular for $248 million in cash. The company purchased a 19.9 percent stake in NeuMoDx in 2018, along with the right to acquire the remaining stake. As part of the 2018 deal, Qiagen has distributed the NeuMoDx 288 and NeuMoDx 96 platforms in Europe and other markets outside the United States.
January 2021—Roche launched the Cobas PIK3CA Mutation Test CE-IVD for patients with advanced or metastatic breast cancer in countries accepting the CE mark. The test was previously available for research use only.
January 2021—Mesa Biotech received 510(k) clearance and CLIA waiver from the FDA for its Accula Strep A test. The strep A cassette, for the molecular detection of group A Streptococcus bacterial nucleic acid, is cleared for diagnosing children and adults and provides results in 30 minutes at the point of care.
January 2021—The FDA authorized the first COVID-19 direct-to-consumer test system—LabCorp’s Pixel COVID-19 Test Home Collection Kit, for use by any person 18 years and older without a prescription.
January 2021—TechLab has partnered with New River Valley COVID-19 Task Force to expand future COVID-19 testing capacity. Under the agreement, the New River Health District, headquartered in Christianburg, Va., secures access to TechLab’s analyte-specific reagents for SARS-CoV-2 for $7 to $9 per use.
January 2021—The Food and Drug Administration approved the next -generation sequencing–based FoundationOne CDx test (Foundation Medicine) as a companion diagnostic to identify fusions in neurotrophic receptor tyrosine kinase genes NTRK1, NTRK2, and NTRK3 in DNA isolated from tumor tissue specimens from patients with solid tumors eligible for treatment with larotrectinib (Vitrakvi, Bayer Healthcare Pharmaceuticals).
